var title_f6_13_6352="Calcified pleural plaques PA";
var content_f6_13_6352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcified pleural plaques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral calcified pleural plaques due to previous asbestos exposure and a right-sided malignant mesothelioma. Chest radiographs shows multiple calcifications en face and in tangent, along the rib cage overlying the lung and along the diaphragm. Complete opacification of the right hemithorax with contralateral mediastinal shift is due to the pleural effusion associated with malignant mesothelioma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6352=[""].join("\n");
var outline_f6_13_6352=null;
var title_f6_13_6353="Gestrinone: International drug information";
var content_f6_13_6353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gestrinone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dimetriose (AU, IE, PT);",
"     </li>",
"     <li>",
"      Dimetrose (BE, BR, IT, LU);",
"     </li>",
"     <li>",
"      Florizel (GB);",
"     </li>",
"     <li>",
"      Nemestran (AR, CH, CZ, ES, MX, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antigonadotropic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endometriosis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 2.5 mg twice weekly starting on first day of cycle with second dose 3 days later, repeated on same two days preferably at same time each week; duration of treatment usually 6 months",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 2.5 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10387 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6353=[""].join("\n");
var outline_f6_13_6353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304051\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978908\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978911\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978907\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821171\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978910\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10387|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6354="MRI pontine glioma";
var content_f6_13_6354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Characteristic imaging findings of a diffuse infiltrating pontine glioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) There is diffuse expansion of the pons with mass effect and displacement of the fourth ventricle on this sagittal T1-weighted image. B) Similar findings are noted on this axial flair image of the same lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6354=[""].join("\n");
var outline_f6_13_6354=null;
var title_f6_13_6355="Fluoroscopic image of tumor ingrowth into a metal biliary stent";
var content_f6_13_6355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluoroscopic image of tumor ingrowth into a metal biliary stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image reveals a filling defect (arrow) within a metal biliary stent due to tumor ingrowth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas G. Adler, MD, FACS, FASGE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6355=[""].join("\n");
var outline_f6_13_6355=null;
var title_f6_13_6356="White sponge nevus";
var content_f6_13_6356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    White sponge nevus of the oral mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large, white plaque is present on the oral mucosa. White sponge nevi represent a rare genetic condition caused by mutations in keratin 4 or keratin 13 genes. Lesions usually first appear during childhood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Carl Allen, DDS, MSD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6356=[""].join("\n");
var outline_f6_13_6356=null;
var title_f6_13_6357="Ethambutol: Pediatric drug information";
var content_f6_13_6357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethambutol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"    see \"Ethambutol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/56/8068?source=see_link\">",
"    see \"Ethambutol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myambutol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Etibi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"      see \"Ethambutol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis, active:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen; treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HIV negative: 15-20 mg/kg/day once daily (maximum: 1 g/day)",
"     <b>",
"      or",
"     </b>",
"     50 mg/kg/dose twice weekly (maximum: 2.5 g/dose) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HIV-exposed/-infected: 15-25 mg/kg/day once daily (maximum: 2.5 g/day) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MAC, secondary prophylaxis or treatment in HIV-exposed/-infected: 15-25 mg/kg/day once daily (maximum: 2.5 g/day) with clarithromycin (or azithromycin) with or without rifabutin (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nontuberculous mycobacterial infection: 15-25 mg/kg/day once daily (maximum: 2.5 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Disseminated",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     (MAC) treatment in patients with advanced HIV infection: 15 mg/kg ethambutol in combination with clarithromycin or azithromycin with/without rifabutin (Griffith, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nontuberculous mycobacterium (",
"     <i>",
"      M. kansasii",
"     </i>",
"     ): Adults: 15 mg/kg/day ethambutol for duration to include 12 months of culture-negative sputum; typically used in combination with rifampin and isoniazid;",
"     <b>",
"      Note:",
"     </b>",
"     Previous recommendations stated to use 25 mg/kg/day for the initial 2 months of therapy; however, IDSA guidelines state this may be unnecessary given the success of rifampin-based regimens with ethambutol 15 mg/kg/day or omitted altogether (Griffith, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis, active:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen; treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 15 mg/kg once daily; Retreatment (previous antituberculosis therapy): 25 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suggested doses by lean body weight (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Daily therapy:",
"     </i>",
"     15-25 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 1600 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Twice weekly directly observed therapy (DOT):",
"     </i>",
"     50 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 2800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 4000 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Three times/week DOT:",
"     </i>",
"     25-30 mg/kg (maximum: 2.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 2400 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Slightly dialyzable (5% to 20%); Administer dose postdialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemofiltration: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003: Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and hemodialysis: 15-25 mg/kg/dose 3 times weekly",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myambutol&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myambutol&reg;: 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with or without food; if GI upset occurs, administer with food. Tablet may be pulverized and mixed with apple juice or apple sauce. Do not mix with other juices or syrups since they do not mask ethambutol's bitter taste or are not stable. Administer ethambutol at least 4 hours before aluminum hydroxide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary tuberculosis (FDA approved in ages &ge;13 years and adults) and other mycobacterial diseases in conjunction with other antimycobacterial agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Myambutol&reg; may be confused with Nembutal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F168092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, disorientation, dizziness, fever, hallucinations, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, erythema multiforme, exfoliative dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acute gout or hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, GI upset, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, hepatotoxicity (possibly related to concurrent therapy), LFTs abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis; symptoms may include decreased acuity, scotoma, color blindness, or visual defects (usually reversible with discontinuation, irreversible blindness has been described)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Infiltrates (with or without eosinophilia), pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, anaphylactoid reaction; hypersensitivity syndrome (cutaneous reactions, eosinophilia, and organ-specific inflammation)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethambutol or any component; optic neuritis, unless clinical judgment determines that it may be used; use in patients unable to discern and report visual changes (eg, very young, unconscious patients)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with ocular defects or impaired renal function; modify dose in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Optic neuropathy including optic neuritis or retrobulbar neuritis characterized by decreased visual acuity, scotoma, color blindness, and/or visual defect has been reported with ethambutol therapy and may be related to dose and treatment duration; irreversible blindness has also been reported. Loss of visual acuity is generally reversible when ethambutol is discontinued promptly, but reversal may require up to a year. Some patients have received ethambutol again after such recovery without recurrence of visual acuity loss. Use only in children whose visual acuity can accurately be determined and monitored; fatal hepatotoxicity has been reported; not recommended for use in children &lt;13 years of age unless benefit outweighs risk of therapy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been seen in animals. There are no adequate and well-controlled studies in pregnant women; there have been reports of ophthalmic abnormalities in infants born to women receiving ethambutol as a component of antituberculous therapy. Use only during pregnancy if benefits outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monthly examination of visual acuity and color discrimination in patients receiving &gt;15 mg/kg/day; periodic renal, hepatic, and hematologic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &sim;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Well distributed throughout the body with high concentrations in kidneys, lungs, saliva, and red blood cells; concentrations in CSF are low; crosses the placenta; excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 20% by the liver to inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.5-3.6 hours (up to 7 hours or longer with renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;50% in urine and 20% excreted in feces as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/56/8068?source=see_link\">",
"      see \"Ethambutol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to physician any visual changes, numbness or tingling in hands or feet, rash, fever, and chills",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/ 1728006 /pubmed\" id=\" 1728006 \" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, CDC, and Infectious Diseases Society of America, \"Treatment of Tuberculosis,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham SM, Bell DJ, Nyirongo S, et al, \"Low Levels of Pyrazinamide and Ethambutol in Children With Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(2):407-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/16436690/pubmed\" id=\"16436690\" target=\"_blank\">",
"        16436690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al, \"An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2007, 175(4):367-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/17277290/pubmed\" id=\"17277290\" target=\"_blank\">",
"        17277290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill S, Regondi I, Grzemska M, et al, \"Children and Tuberculosis Medicines: Bridging the Research Gap,\"",
"      <i>",
"       Bull World Health Organ",
"      </i>",
"      , 2008, 86(9):658.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/18797634/pubmed\" id=\"18797634\" target=\"_blank\">",
"        18797634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14:455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/13/6357/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13286 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6357=[""].join("\n");
var outline_f6_13_6357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168048\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168049\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047287\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047281\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168024\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168009\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047283\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168094\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168092\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047293\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047280\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047279\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299290\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168018\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047286\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047278\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047292\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047285\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=related_link\">",
"      Ethambutol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/56/8068?source=related_link\">",
"      Ethambutol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6358="Fluvoxamine: Patient drug information";
var content_f6_13_6358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluvoxamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     see \"Fluvoxamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41320?source=see_link\">",
"     see \"Fluvoxamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6195103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Luvox&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Fluvoxamine;",
"     </li>",
"     <li>",
"      Apo-Fluvoxamine&reg;;",
"     </li>",
"     <li>",
"      Luvox&reg;;",
"     </li>",
"     <li>",
"      Novo-Fluvoxamine;",
"     </li>",
"     <li>",
"      Nu-Fluvoxamine;",
"     </li>",
"     <li>",
"      PMS-Fluvoxamine;",
"     </li>",
"     <li>",
"      Rhoxal-fluvoxamine;",
"     </li>",
"     <li>",
"      Riva-Fluvox;",
"     </li>",
"     <li>",
"      Sandoz-Fluvoxamine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obsessive-compulsive problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat social anxiety problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702155",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluvoxamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures or are on seizure drugs, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any natural products, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12495 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6358=[""].join("\n");
var outline_f6_13_6358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195103\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020320\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020322\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020321\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020326\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020327\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020329\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020324\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020325\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020330\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020331\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=related_link\">",
"      Fluvoxamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41320?source=related_link\">",
"      Fluvoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6359="Overview of obstructive sleep apnea in adults";
var content_f6_13_6359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6359/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6359/contributors\">",
"     Kingman P Strohl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6359/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6359/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6359/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/13/6359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a common chronic disorder that often requires lifelong care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardinal features in adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive apneas, hypopneas, or respiratory effort related arousals.",
"     </li>",
"     <li>",
"      Daytime symptoms attributable to disrupted sleep, such as sleepiness, fatigue, or poor concentration.",
"     </li>",
"     <li>",
"      Signs of disturbed sleep, such as snoring, restlessness, or resuscitative snorts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OSA is an important disorder because patients are at increased risk for poor neurocognitive performance and medical disorders, due to repeated arousals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia during sleep over months to years. The severity and duration of OSA necessary for development of these sequelae vary among individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, severe untreated OSA has been associated with increased all-cause and cardiovascular mortality.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, pathophysiology, and outcome of OSA in adults are reviewed here. The definition, clinical presentation, diagnosis, and treatment are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that up to 26 percent of adults are at high risk for OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The prevalence of OSA in general North American populations is approximately 20 percent if defined as an apnea hypopnea index (AHI) greater than five events per hour (the AHI is the number of apneas and hypopneas per hour of sleep) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, it is 2 to 9 percent if defined as an AHI greater than five events per hour accompanied by at least one symptom that is known to respond to treatment (eg, daytime sleepiness) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Therefore, it is common to be minimally symptomatic and have an AHI in an abnormal range.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ndash; The prevalence of OSA increases from 18 to 45 years of age, with a plateau occurring at 55 to 65 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnicity and race &ndash; OSA is more prevalent in African Americans who are younger than 35 years old, compared with Caucasians of the same age group. This observation is independent of body weight. The prevalence of OSA in Asia is similar to that in the United States, despite having a lower mean body weight. These observations suggest that race may be an important risk factor, possibly related to differences in craniofacial structure [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/1,5\">",
"       1,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gender &ndash; Three to 4 percent of women and 6 to 9 percent of men have OSA, when defined as an AHI greater than five events per hour accompanied by daytime sleepiness or a cardiovascular morbidity (eg, hypertension). Some of the gender differences may be age-related, although there is little gender difference among adolescents or after the sixth decade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brainstem nuclei coordinate the ventilatory actions of upper airway muscles, chest wall muscles, and the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. Phasic (ie, inspiratory, expiratory) neural output induces cyclic increases and decreases of ventilatory muscle activation; the result is a series of breaths that comprise the ventilatory rhythm. Whether this rhythm is regular, irregular, or periodic over time is determined by the ventilatory control system.",
"   </p>",
"   <p>",
"    Upper airway patency is maintained by the bony and cartilaginous structures surrounding the naso- and oropharynx, plus twelve pairs of skeletal muscles. Patients with OSA have a reduced upper airway size due to excess surrounding soft tissue or a highly compliant airway. A reduced airway size, combined with diminished neural output to the upper airway muscles during sleep and at apnea onset, can result in partial or complete upper airway collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. The results are obstructive and mixed apneas. The tendency of the upper airway to collapse is determined by its critical closing pressure (Pcrit) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H4#H4\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Obstructive apnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H6#H6\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Mixed apnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apneas recur, at least in part, through a process referred to as \"loop gain\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. This can be conceptualized as follows. Apneas occur when the respiratory drive is less than the threshold for inspiratory muscle activation and for maintaining upper airway patency during sleep. As apnea progresses, respiratory drive increases until a threshold is passed. Inspiration then occurs. If an overshoot in ventilation drives down carbon dioxide levels, the respiratory drive may fall below the threshold for inspiration to occur. Thus, the next apnea results from overcompensation for the prior apnea.",
"   </p>",
"   <p>",
"    Individual variations in Pcrit and loop gain may explain why there exists a spectrum of OSA severity, as well as the appearance of central apneas during positive airway pressure titration (ie, complex sleep apnea) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=see_link\">",
"     \"Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9969828\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definite risk factors for OSA include obesity, craniofacial abnormalities, and upper airway soft tissue abnormalities. Potential risk factors include heredity, smoking, and nasal congestion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity is the best documented risk factor for OSA. The prevalence of OSA progressively increases as the body mass index and associated markers (eg, neck circumference, waist-to-hip ratio) increase [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Craniofacial and upper airway soft tissue abnormalities each increase the likelihood of having or developing OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"       2",
"      </a>",
"      ]. Examples of such abnormalities include an abnormal maxillary or short mandibular size, a wide craniofacial base, tonsillar hypertrophy, and adenoid hypertrophy.",
"     </li>",
"     <li>",
"      Adult sleep apnea is a complex disease. It is not due to a single mutation or protein action. This conclusion is supported by evidence that only about one-fourth of the prevalence of OSA or an elevated apnea hypopnea index (AHI) has a genetic basis. In addition, the inheritance of obesity and craniofacial abnormalities explains only a fraction of the two- to four-fold increased likelihood of OSA or an elevated AHI among the family members of patients with OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/6\">",
"       6",
"      </a>",
"      ]. Familial clustering of OSA does not warrant testing asymptomatic family members.",
"     </li>",
"     <li>",
"      Current smokers (but not past smokers) are nearly three times more likely to have OSA than never smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nasal congestion confers an approximately two-fold increase in the prevalence of OSA compared with controls, regardless of the cause of nasal congestion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"       2",
"      </a>",
"      ]. This is probably related to increased resistance due to decreased nasal patency [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to recognize that while these factors may be associated with OSA, their elimination is not necessarily curative of OSA. As examples, weight loss or correction of a craniofacial abnormality may resolve OSA, but smoking cessation and management of nasal congestion or septal deviation have a less predictable impact [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OSA has also been associated with all cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and chronic medical illnesses, such as coronary heart disease and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/12\">",
"     12",
"    </a>",
"    ], hypoventilation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/13\">",
"     13",
"    </a>",
"    ], chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/14\">",
"     14",
"    </a>",
"    ], idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/15\">",
"     15",
"    </a>",
"    ], and mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=see_link\">",
"     \"Sleep related breathing disorders and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snoring and daytime sleepiness are the most common presenting complaints of OSA. Additional symptoms and signs include restless sleep, periods of silence terminated by loud snoring, fatigue, poor concentration, nocturnal angina, and awakening with a sensation of choking, gasping, or smothering (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    ). The clinical manifestations of OSA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-laboratory polysomnography is the first-line diagnostic study when OSA is suspected. However, in-home portable monitoring is an acceptable alternative for some patients who are suspected of having OSA (",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Diagnosis of OSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISEASE SPECTRUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy individuals may experience periods of absent or decreased respiration at sleep onset or during rapid eye movement (REM) sleep. Events generally last less than 10 seconds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are not repetitive. An isolated apnea lasting up to 30 seconds occurs normally during REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"     5",
"    </a>",
"    ]. Episodes are infrequent, but may be accompanied by hypoxemia or followed by arousals or sleep-state changes. There are no known clinical sequelae.",
"   </p>",
"   <p>",
"    Snoring is common and its frequency increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who snore are seven times more likely than non-snorers to develop OSA if they snore loudly on a regular basis. The pathophysiology, consequences, evaluation, and treatment of snoring are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22022?source=see_link\">",
"     \"Overview of snoring in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=see_link\">",
"     \"Treatment of adults with snoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients who are diagnosed with OSA have an AHI greater than 15 events per hour, but do not exhibit excessive sleepiness and do not have sleep-related comorbidities (",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Such patients may have an increased risk of developing hypertension. In contrast, other patients who are diagnosed with OSA exhibit excessive sleepiness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have sleep-related comorbidities (",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Such patients are traditionally classified as having mild, moderate, or severe disease on the basis of symptoms or polysomnography AHI indices [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mild",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients traditionally classified as having mild OSA are those with an AHI between 5 and 15 respiratory events per hour of sleep. Such patients may be relatively asymptomatic or report sedentary (ie, passive) daytime sleepiness, becoming noticeable once the patient is unstimulated. The daytime sleepiness often does not impair daily life, although it may be recognized by family members. Alternatively, daytime sleepiness may become apparent to the patient only after it improves due to weight loss, alcohol abstinence, or treatment of OSA. The sleep stages and slow wave sleep are generally preserved in mild OSA and systemic hypertension, cor pulmonale, and polycythemia are generally absent. Approximately 30 percent of patients with mild OSA will tolerate and respond to treatment, compared with placebo. Specifically, positive airway pressure therapy may reduce daytime sleepiness and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Moderate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients traditionally classified as having moderate OSA are those with an AHI between 15 and 30 respiratory events per hour of sleep. Such patients are typically aware of daytime sleepiness and take steps to avoid falling asleep at inappropriate times (eg, taking a nap or avoiding driving long distances). They are able to continue their daily activities, but at reduced levels, and they may have an increased incidence of motor vehicle violations or accidents. Systemic hypertension may co-exist, but daytime signs or symptoms of cor pulmonale are usually absent. Sleep fragmentation is observed in moderate OSA, but the progression of sleep stages is better conserved than with severe disease. Patients with moderate OSA usually respond to positive airway pressure therapy with an improvement in daytime sleepiness, quality of life, and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients classified as having severe OSA are those with an AHI greater than 30 respiratory events per hour of sleep",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an oxyhemoglobin saturation below 90 percent for more than 20 percent of the total sleep time. Such patients more often have daytime sleepiness that interferes with normal daily activities. They tend to fall asleep often during the day (and in a sitting posture) and are at risk for accidental injury from sleepiness. In addition, cardiopulmonary failure, nocturnal angina, polycythemia, or cor pulmonale may result from hypoxemia. Patients with severe OSA benefit from prompt therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. Treatment will improve daytime sleepiness, hypertension, and, possibly, other hypoxemia-related abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are interventions of documented benefit in patients with OSA. These include behavioral modifications, weight loss, and OSA-specific therapies, such as positive airway pressure, oral appliances, and surgery . The treatment of OSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA are at increased risk of adverse clinical outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with untreated severe OSA (ie, an apnea hypopnea index greater than 30 events per hour) appear to have a three- to six-fold increased risk of all-cause mortality compared to individuals without OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3,7,8\">",
"       3,7,8",
"      </a>",
"      ]. In contrast, patients with untreated mild OSA may not be at increased risk for mortality compared with individuals without OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Untreated OSA may also be associated with the development of heart failure in men, particularly in those who have an AHI &ge;30 events per hour of sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=see_link\">",
"       \"Sleep related breathing disorders and stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OSA is associated with excessive daytime sleepiness, inattention, and fatigue, which may impair daily function, induce or exacerbate cognitive deficits, and increase the likelihood of errors and accidents [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/3,16,18,20\">",
"       3,16,18,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=see_link\">",
"       \"Definition and consequences of sleep deprivation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Motor vehicle crashes are two to three times more common among patients with OSA than without OSA; this represents an impact on morbidity and mortality that is similar to the cardiovascular sequelae of OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/20\">",
"       20",
"      </a>",
"      ]. Treatment with CPAP reduces self-reported crashes by 50 to 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=see_link\">",
"       \"Performance and safety risks of sleep deprivation and sleep disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with OSA have a propensity for night-time cardiac death, which differs from patients without OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with OSA may be at greater risk for perioperative complications such as postoperative oxygen desaturation, acute respiratory failure, postoperative cardiac events, and intensive care unit transfers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OSA is associated with diabetes or insulin resistance, although this may be due, in part, to risk factors common to both conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with OSA use more medical resources, and have greater medical disability than individuals without OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6359/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       \"Patient information: Daytime sleepiness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardinal features of obstructive sleep apnea (OSA) include irregular and abnormal respiratory patterns during sleep (eg, obstructive apneas, hypopneas, respiratory effort related arousals), loud snoring and snorts during sleep, symptoms attributable to disrupted sleep (eg, sleepiness, fatigue, poor concentration), and signs of disturbed sleep (eg, snoring, restlessness, resuscitative snorts). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of OSA in the general adult population is approximately 20 percent if it is defined as an apnea hypopnea index greater than five events per hour (the apnea hypopnea index [AHI] is the number of apneas and hypopneas per hour of sleep). In contrast, the prevalence is only 2 to 9 percent if defined as an AHI greater than five events per hour, accompanied by at least one symptom or sign of OSA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definite risk factors for OSA include obesity, craniofacial abnormalities, and upper airway soft tissue abnormalities. Potential risk factors include loud snoring, heredity, smoking, and nasal congestion. (See",
"      <a class=\"local\" href=\"#H9969828\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Snoring and daytime sleepiness are common manifestations of OSA. Additional symptoms and signs include restless sleep, periods of silence terminated by loud snorts or snoring, nocturnal angina, poor concentration, and awakening with a sensation of choking, gasping, or smothering (",
"      <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"       table 1",
"      </a>",
"      ). The physical exam can be normal, although obesity, elevated blood pressure, a narrow airway, and a large neck circumference are common. Clinical manifestations of OSA are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In-laboratory polysomnography is the preferred diagnostic study when OSA is suspected (",
"      <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"       algorithm 1",
"      </a>",
"      ). The diagnosis of OSA is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are several interventions that may benefit patients with OSA. These include behavior modifications and OSA-specific therapies (eg, positive airway pressure, oral appliances, and surgery). The treatment of OSA is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potential sequelae of OSA include mishaps due to excessive daytime sleepiness, inattention, or fatigue, as well as systemic hypertension, mild pulmonary hypertension, and cardiovascular morbidities. Patients with severe OSA (ie, AHI &gt;30 events per hour) appear to be at increased risk for all-cause mortality. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/1\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/2\">",
"      Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/3\">",
"      Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ 2009; 108:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/4\">",
"      Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J 2009; 33:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/5\">",
"      Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev 2010; 90:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/6\">",
"      Redline S, Tishler PV. The genetics of sleep apnea. Sleep Med Rev 2000; 4:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/7\">",
"      Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/8\">",
"      Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6:e1000132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/9\">",
"      Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/10\">",
"      Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/11\">",
"      Loke YK, Brown JW, Kwok CS, et al. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2012; 5:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/12\">",
"      Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/13\">",
"      Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/14\">",
"      Martinez CH, Han MK. Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. Med Clin North Am 2012; 96:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/15\">",
"      Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/16\">",
"      Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011; 306:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/17\">",
"      Lin WC, Winkelman JW. Obstructive sleep apnea and severe mental illness: evolution and consequences. Curr Psychiatry Rep 2012; 14:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/18\">",
"      Strohl, K, Bonnie, R, Findley, L, et al. Sleep apnea, sleepiness and driving risk. American Journal of Respiratory and Critical Care Medicine 1999; 150:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/19\">",
"      Giles TL, Lasserson TJ, Smith BH, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; :CD001106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/20\">",
"      George CF. Sleep apnea, alertness, and motor vehicle crashes. Am J Respir Crit Care Med 2007; 176:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6359/abstract/21\">",
"      Leger D, Bayon V, Laaban JP, Philip P. Impact of sleep apnea on economics. Sleep Med Rev 2012; 16:455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7683 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6359=[""].join("\n");
var outline_f6_13_6359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9969828\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISEASE SPECTRUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mild",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Moderate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Severe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7683|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/5/22622\" title=\"algorithm 1\">",
"      OSA diagnosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/10/12460\" title=\"table 1\">",
"      Clinical features OSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=related_link\">",
"      Definition and consequences of sleep deprivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=related_link\">",
"      Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22022?source=related_link\">",
"      Overview of snoring in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=related_link\">",
"      Performance and safety risks of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=related_link\">",
"      Sleep related breathing disorders and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=related_link\">",
"      Sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=related_link\">",
"      Treatment of adults with snoring",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6360="Folliculitis decalvans";
var content_f6_13_6360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Folliculitis decalvans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous inflammatory papules and pustules are present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6360=[""].join("\n");
var outline_f6_13_6360=null;
var title_f6_13_6361="Peripheral venous access in adults";
var content_f6_13_6361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peripheral venous access in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Robert L Frank, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6361/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/13/6361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27755068\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral venous cannulation, among the most common medical procedures, has revolutionized the practice of medicine. Peripheral intravenous (IV) catheters allow for the safe infusion of medications, hydration fluids, blood products, and nutritional supplements.",
"   </p>",
"   <p>",
"    This topic will discuss the indications, contraindications, performance, and complications of peripheral venous catheter placement. Emergency vascular access in children and central venous catheter placement are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663520\">",
"    <span class=\"h1\">",
"     INDICATIONS, CONTRAINDICATIONS, AND DIFFICULTY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755075\">",
"    <span class=\"h2\">",
"     Indications for venous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most often, intravenous (IV) access is obtained to provide therapies that cannot be administered or are less effective if given by alternative routes. As examples, IV hydration and nutritional support can be given to a patient with severe vomiting or abdominal pain from a surgical condition. Certain medications are more effective when given intravenously due to rapid onset or increased bioavailability. Some clinical situations, such as cardiac arrest, require treatment using IV medications; blood products must be given intravenously. In some instances, IV catheters are left in place when medications are given intermittently over a longer period (eg, long-term antibiotic therapy) or in case of a potential emergency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755089\">",
"    <span class=\"h2\">",
"     Indications for peripheral versus central venous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to obtain peripheral rather than central venous access depends upon clinical circumstances. In general, peripheral catheters are preferred when IV access is required for shorter periods, when direct access to the central circulation is unnecessary, and when smaller gauge catheters suffice. Peripheral access is generally safer, easier to obtain, and less painful than central access. In patients taking anticoagulants, peripheral access allows for direct compression of puncture sites and fewer hematoma-related complications compared with the sites used for central venous catheters.",
"   </p>",
"   <p>",
"    Central venous catheters are often preferred in patients receiving sclerosing medications that can damage peripheral veins or being treated with vasopressors, which can cause injury if extravasated. Central venous access may also be preferable in patients with severe volume depletion or in whom peripheral venous catheter placement has a low likelihood of success (ie, frequent users of illicit IV drugs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link&amp;anchor=H3099781#H3099781\">",
"     \"Placement of femoral venous catheters\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3103243#H3103243\">",
"     \"Overview of central venous access\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15275188\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few contraindications to the placement of peripheral venous catheters. Most concern problems with cannulation at a specific site. The sole absolute contraindication is when appropriate therapy can be provided by a less invasive route (eg, orally). Guidelines about appropriate sites for the placement of peripheral venous catheters are described separately. (See",
"    <a class=\"local\" href=\"#H27755111\">",
"     'Site selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52513128\">",
"    <span class=\"h2\">",
"     Anticipated difficulty",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to observational data, factors associated with difficulty placing a peripheral IV catheter in an adult include obesity, underweight, clinician inexperience, and clinician judgement of poor peripheral venous access [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a prospective study of IV placement in 563 consecutive emergency department patients, difficult venous access was predicted by paucity or absence of visible or palpable peripheral veins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If difficulty is anticipated or apparent when it is critical to obtain access, alternative approaches include intraosseous and central venous catheters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755096\">",
"    <span class=\"h1\">",
"     MATERIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755104\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necessary materials for obtaining peripheral venous access include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral venous catheters of appropriate size",
"     </li>",
"     <li>",
"      Connective tubing and IV fluid",
"     </li>",
"     <li>",
"      Skin preparation materials (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dressings",
"     </li>",
"     <li>",
"      Tape or a commercial device to secure the catheter",
"     </li>",
"     <li>",
"      Clean gloves and eye protection &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If fluid administration is not required and the catheter is placed for intermittent therapy or anticipated need, a cap is placed atop the catheter. In such cases, a small syringe filled with a flushing solution (eg, isotonic saline) is required to ensure the catheter&rsquo;s patency.",
"   </p>",
"   <p>",
"    Other materials that may be needed when obtaining peripheral venous access include a topical anesthetic to minimize the pain of venipuncture, fluid warmers, and pressure infusers. If a catheter is placed over a joint, a splint may help to reduce movement and decrease the risk of dislodging the catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209344\">",
"    <span class=\"h2\">",
"     Catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV) catheters in common use today are pliable plastic tubes with an inner needle obturator (over-the-needle catheters) (",
"    <a class=\"graphic graphic_picture graphicRef55791 \" href=\"UTD.htm?23/12/23751\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/4\">",
"     4",
"    </a>",
"    ]. Steel needles, such as butterfly needles, may be appropriate for blood draws, but should not be used for prolonged IV therapy due to the risk of vein injury and extravasation of fluids or medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/5\">",
"     5",
"    </a>",
"    ]. Catheter material and the risk of phlebitis and infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter material'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H15#H15\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Phlebitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral catheters range in size from 24 (smaller) to 14 (larger) gauges. Twenty-two to 20 gauge catheters are typically used for medication administration or infusion of moderate volumes of fluid. Infusion of large fluid volumes or blood products typically requires larger sizes (eg, 18 to 16 gauge). The smallest appropriate needle size should be used, as smaller catheters cause less trauma and phlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheters range in length from 2 to 3 cm (0.75 to 1.25 inches). Longer catheters (5 to 15 cm; 2 to 6 inches) may be beneficial for placement proximal to the antecubital fossa by reducing the risk of dislodgement when the patient moves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    To reduce the risk of injury, the needles in most catheters in current use can be retracted into a needle guard by pushing a button on the flashback chamber after the catheter is inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755111\">",
"    <span class=\"h1\">",
"     SITE SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209385\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many sites can be used for peripheral intravenous (IV) access, and they vary in their ease of cannulation and potential risks. Site selection varies according to clinical circumstances, expected duration of treatment, and the condition of the extremities.",
"   </p>",
"   <p>",
"    In general, distal extremity sites should be used first, saving more proximal sites for subsequent cannulation, if needed. Placing an IV in a vein distal to a site that was previously punctured can lead to extravasation of fluids and hematoma formation. Larger veins are generally more easily cannulated and are preferable to smaller veins in the same region. Veins of the upper extremity are preferred due to the increased risk of thrombosis and thrombophlebitis with venous cannulation of the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Whenever possible, avoid using the dominant upper extremity.",
"   </p>",
"   <p>",
"    Sites over joints (eg, antecubital fossa) should be avoided if possible due to the increased risk of catheter dislodgement and kinking, and the need to then immobilize the joint to reduce these risks. Peripheral IV catheters used for trauma resuscitation are an exception to this rule and are routinely placed in the larger veins of the antecubital fossa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929754#H1929754\">",
"     \"Initial management of trauma in adults\", section on 'Circulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraindications to the use of a particular extremity include the presence of an arteriovenous fistula (catheter can alter venous blood flow or damage the fistula) and a history of mastectomy or lymph node dissection (catheter can exacerbate impaired lymphatic drainage) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/5\">",
"     5",
"    </a>",
"    ]. Venous catheter placement should be avoided at a site that may interfere with an anticipated procedure (eg, an injured extremity that requires surgery).",
"   </p>",
"   <p>",
"    Veins that are firm to palpation may be sclerosed (eg, from IV drug abuse) and should be avoided as should veins with evidence of phlebitis or thrombosis. Venous puncture at sites where catheter placement was recently attempted should also be avoided, especially if a hematoma formed (ie, vein was &ldquo;blown&rdquo;) following the previous attempt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link&amp;anchor=H10#H10\">",
"     \"Superficial thrombophlebitis of the lower extremity\", section on 'Clinical features and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placement of an IV through infected tissue is not advised due to the risk of introducing a systemic infection. In addition, peripheral IV catheters should not be placed through burned tissue or in extremities with massive edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209392\">",
"    <span class=\"h2\">",
"     Anatomy and vein selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The veins of the dorsum of the hand are often the most accessible sites for peripheral cannulation (",
"    <a class=\"graphic graphic_figure graphicRef70665 \" href=\"UTD.htm?43/15/44281\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"UTD.htm?18/3/18480\">",
"     figure 2",
"    </a>",
"    ). As an example, the dorsal metacarpal veins are usually visible and palpable and make good sites for IV catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/5\">",
"     5",
"    </a>",
"    ]. These veins merge into the dorsal venous network (or arch) and then form the cephalic vein, which runs along the lateral distal forearm. The cephalic vein is usually visible and palpable and therefore another good site for cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/10\">",
"     10",
"    </a>",
"    ]. The volar forearm also contains several veins that can be cannulated, including the median antebrachial veins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antecubital fossa, though not a primary choice for nonemergent IV access, contains several accessible veins, including the cephalic, median cubital, and basilic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/11\">",
"     11",
"    </a>",
"    ]. These veins are usually large and easily cannulated and provide a useful option when emergent IV access is needed. Veins in the proximal arm are more safely cannulated using ultrasound guidance. They include the more proximal portions of the basilic, cephalic, and brachial veins. If catheter placement is attempted in these proximal veins without ultrasound guidance, there is an increased risk of arterial puncture and nerve injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the arm, leg and neck veins can be used to obtain peripheral IV access. The external jugular vein, which drains into the subclavian, is a large vein in the neck that is easily cannulated, even in patients with severe volume depletion or otherwise poor extremity access (",
"    <a class=\"graphic graphic_figure graphicRef53785 \" href=\"UTD.htm?41/3/42038\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/13\">",
"     13",
"    </a>",
"    ]. Placing the patient&rsquo;s bed in a head-down (ie, Trendelenburg) position or having them perform a Valsalva maneuver often enlarges the vein making cannulation easier. When inserting the catheter, avoid the valves in the external jugular vein, which can impair function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27755140\">",
"     'Vein dilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Veins of the leg, including the greater saphenous vein at the level of the medial malleolus and the dorsal metatarsal veins on the dorsum of the foot, are often accessible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/15\">",
"     15",
"    </a>",
"    ]. However, lower extremity sites should be used only if veins in the arm cannot be cannulated (",
"    <a class=\"graphic graphic_figure graphicRef73200 \" href=\"UTD.htm?16/51/17210\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2209385\">",
"     'Guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755118\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755126\">",
"    <span class=\"h2\">",
"     Consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implied (presumed) consent is felt adequate for a procedure such as placement of a peripheral venous catheter where the risks and benefits are common knowledge to \"persons of average intelligence\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/16\">",
"     16",
"    </a>",
"    ]. For IV catheter placement, consent can be assumed if the patient extends their arm for the procedure to be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/17\">",
"     17",
"    </a>",
"    ]. Some patients may be apprehensive about IV placement and in nonemergent cases, it is important to take some time to explain the reason for venous catheterization, risks and benefits, alternatives, expected duration of therapy, and the pain involved, and to allow the patient an opportunity to ask questions.",
"   </p>",
"   <p>",
"    Obtaining IV access in uncooperative patients is challenging. It is important to determine why the patient will not or cannot cooperate. If the patient lacks the capacity to make reasoned medical decisions and has a potentially life or limb-threatening condition requiring urgent intervention, the use of restraints may be necessary. Chemical restraint is preferred, but temporary use of physical restraints may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient is alert and has capacity but will not cooperate due to fear or anxiety, provide reassurance. Administration of a short-acting anxiolytic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) prior to the procedure may be beneficial, as may allowing a parent, family member, or friend to help comfort the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755133\">",
"    <span class=\"h2\">",
"     Basic preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keep the patient warm and relaxed; both excessive cold and anxiety stimulate the sympathetic nervous system and can cause vasoconstriction of superficial vessels, thus making cannulation more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who are excessively anxious may benefit from a small dose of a short-acting anxiolytic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) prior to the procedure.",
"   </p>",
"   <p>",
"    Excessive hair around catheter sites may be clipped to ease cannulation and improve dressing adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/5\">",
"     5",
"    </a>",
"    ]. Do not shave hair because this increases the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/4\">",
"     4",
"    </a>",
"    ]. If a topical anesthetic is used, allow sufficient time for it to take effect. If possible, use the patient&rsquo;s nondominant extremity to reduce inconvenience and the effect of extravasation, should it occur.",
"   </p>",
"   <p>",
"    The practitioner placing the IV and the patient should both be comfortable throughout the procedure. If possible, place patients in a supine position to avoid lightheadedness from pain or the sight of blood. Place the extremity with the venipuncture site on a stable surface below heart level to allow gravity to enhance venous dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209949\">",
"    <span class=\"h2\">",
"     Prevention of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before venipuncture is attempted, take appropriate steps to protect the patient and healthcare worker from infection. Wash your hands, and wear clean gloves and protective eye wear. Do not touch the puncture site after it has been cleaned with an appropriate solution (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ). Prevention of infection associated with IV catheters, including cleaning agents and sterile technique, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755140\">",
"    <span class=\"h2\">",
"     Vein dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple methods for enhancing venous dilation to facilitate cannulation have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/20\">",
"     20",
"    </a>",
"    ]. Placing the anticipated cannulation site below the level of the heart uses gravity to reduce venous return, which causes blood to pool and veins to distend [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Lightly tapping or gently stroking the vein along its length in a proximal to distal direction causes venous distension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Another simple, effective way to dilate veins consists of having the patient alternately clench and relax their fist [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevating skin temperatures to 39&deg; to 42&deg;C at the cannulation site causes venous dilation. This can be accomplished by placing the site in warm water or by applying a warm compress (eg, warm moist cloths, warming packs, heated carbon fiber mitts) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/21,22,25-27\">",
"     21,22,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proximal compression, most often using a thin rubber tourniquet placed 5 to 10 cm proximal to the anticipated venipuncture site, impedes venous return and enhances venous dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/21\">",
"     21",
"    </a>",
"    ]. Tourniquet pressures should be greater than venous pressure, but less than arterial pressure to allow arterial inflow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. Other devices similar to tourniquets may be used, such as blood pressure cuffs and Esmarch bandages. If a blood pressure cuff is used, inflate it no higher than the diastolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Avoid excessive pressure and prolonged application of the tourniquet to reduce the risk of vein injury and hematoma formation, especially in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An Esmarch bandage is similar to the rubber tourniquets commonly used, but is 7.5 to 25 cm (3 to 10 inches) in width, and each roll is several hundred centimeters long. The Esmarch bandage is placed at the proximal end of the involved limb, and the limb is then wrapped circumferentially in a proximal to distal direction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/32\">",
"     32",
"    </a>",
"    ]. This squeezes blood from the proximal to the distal end of the limb, thereby dilating the veins.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    ointment applied to the venipuncture site and left for two minutes causes venous dilation and does not appear to cause deleterious changes in blood pressure, even in hypotensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the placement of larger intravenous (IV) catheters, a technique for dilating veins similar to Bier block regional anesthesia has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/34\">",
"     34",
"    </a>",
"    ]. After a small gauge IV catheter is placed, usually in the hand, the tourniquet is left in place. A volume of isotonic crystalloid (60 to 300 mL) is then infused. This fluid distends the surrounding collateral veins, allowing for placement of a larger gauge catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663664\">",
"    <span class=\"h2\">",
"     Tools for locating veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;When no veins are readily visible or palpable, any of several transillumination devices can be used to locate veins for cannulation. One such device uses infrared light, which reflects off tissue surrounding the veins, but not the vein itself (eg, The VeinViewer&reg;, Luminetx, Memphis, TN) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/35\">",
"     35",
"    </a>",
"    ]. Other devices use a light frequency that causes deoxygenated venous blood to appear darker than surrounding tissues (eg, Veinlite LED&reg;, TransLite, Sugarland, TX) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients with veins not easily seen or palpated, Doppler ultrasound can be used to identify veins larger than 2 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755147\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venipuncture is a painful procedure, but analgesia is not routinely provided outside the operating theater [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/37\">",
"     37",
"    </a>",
"    ]. Nevertheless, topical and subcutaneous anesthetics reduce the pain and anxiety associated with IV catheter insertion, and they should be used whenever possible. Multiple methods are available for providing analgesia prior to venipuncture, including intradermal injection, topical medication, and technologies such as iontophoresis. A thorough discussion of topical anesthetics is found separately; a brief description of selected analgesic techniques for peripheral venous cannulation is provided here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intradermally injected local anesthetics are the traditional method of anesthetizing a puncture site. One percent buffered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injected subcutaneously provides rapid anesthesia and does not appear to decrease successful catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/38\">",
"     38",
"    </a>",
"    ]. This method reduces the pain from venipuncture, but involves a separate injection, which itself can cause pain, anxiety, and may distort puncture site anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Avoid intradermal anesthetics that contain epinephrine, which can cause the vein to constrict [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of topical anesthetics can be used to reduce the pain of venipuncture:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EMLA, the eutectic mixture of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      , reduces pain but requires approximately one hour to achieve peak effect. If used, 1 to 2 grams should be applied per 10 cm",
"      <sup>",
"       2",
"      </sup>",
"      of skin and then covered with an occlusive dressing. EMLA is generally safe, but can cause methemoglobinemia with prolonged use or in those who are predisposed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H11#H11\">",
"       \"Topical anesthetics in children\", section on 'EMLA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LMX&trade; (formerly ELA-max) is a topical preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      encapsulated in liposomes, which are spherical, microscopic, phospholipid-based carriers that promote passage of the anesthetic through intact skin. LMX appears to have similar efficacy to EMLA in preventing pain from venipuncture, but takes only 30 minutes to exert its effect. Dosing is similar to EMLA: apply 1 to 2 grams per 10 cm",
"      <sup>",
"       2",
"      </sup>",
"      of skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H21#H21\">",
"       \"Topical anesthetics in children\", section on 'Liposomal lidocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"       Tetracaine",
"      </a>",
"      , an ester anesthetic, can be applied as a 4 percent cream, a 5 percent gel (Amethocaine), or a 5 percent liposomal encapsulated cream (LET). Its efficacy and time of onset are similar to EMLA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"       \"Topical anesthetics in children\", section on 'LET'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each method above has advantages and disadvantages, but all seem to provide similar degrees of anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/44\">",
"     44",
"    </a>",
"    ]. If time allows, topical agents are a good approach, but they may require 30 to 60 minutes to achieve maximum effect.",
"   </p>",
"   <p>",
"    Iontophoresis, the application of a small electrical current to move ionized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    through intact skin, has been used to provide local analgesia. Iontophoresis provides pain relief from venipuncture within 10 to 20 minutes. The technique can cause minor skin irritation and blistering. Similarly, sonophoresis, the use of low frequency ultrasound to facilitate skin penetration of a local anesthetic, has been shown to be fast (15 to 20 seconds of ultrasound time followed by five minutes of local anesthetic application) and effective in reducing pain from venipuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. A disadvantage of such techniques is the need for relatively expensive equipment.",
"   </p>",
"   <p>",
"    Researchers have assessed the use of a single pulse of an erbium: yttrium-aluminum-garnet laser to remove the stratum corneum, thereby improving the penetration of local anesthetic. While the technique was found to reduce the pain of IV cannulation in volunteers within minutes, the cost of the laser device is prohibitive (approximately $2000 US) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755154\">",
"    <span class=\"h1\">",
"     CATHETER INSERTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755162\">",
"    <span class=\"h2\">",
"     Traditional percutaneous technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an appropriate site is selected, use the following technique to place the catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a tourniquet proximal to the intended site (",
"      <a class=\"graphic graphic_picture graphicRef62529 \" href=\"UTD.htm?34/25/35217\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cleanse the skin, being careful not to contaminate the puncture site after the skin is cleansed. A local anaesthetic may be injected (",
"      <a class=\"graphic graphic_picture graphicRef75311 \" href=\"UTD.htm?31/55/32624\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hold the area steady with the nondominant hand, and use the thumb to pull gently on the vein. This reduces movement of the vein when inserting the needle. Avoid applying excessive pressure, which will collapse the vein.",
"     </li>",
"     <li>",
"      Hold the catheter in the dominant hand between the thumb and forefinger with the bevel facing upwards (",
"      <a class=\"graphic graphic_picture graphicRef57369 \" href=\"UTD.htm?10/3/10289\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Approach the vein with the needle at a low angle, generally about 10 to 30 degrees from the skin surface. Puncture the skin, and enter the vein using a slow, smooth, continuous movement. A flash of blood in the flash back chamber of the catheter indicates that the needle has entered the vein.",
"     </li>",
"     <li>",
"      Advance the catheter another 1 to 2 millimeters to ensure that the catheter tip, which sits back slightly from the needle lumen, lies completely within the vein (",
"      <a class=\"graphic graphic_picture graphicRef70200 \" href=\"UTD.htm?3/45/3793\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Place the tip of the dominant index finger against the small tab that extends up from the top of the hub of the catheter. Advance the catheter into the vein by extending the dominant index finger, thereby exerting pressure against the small tab with the fingertip. Maintain slight traction on the vein with the nondominant hand to prevent vein movement while the catheter advances. If the catheter is within the vessel lumen, it should advance easily and relatively painlessly (",
"      <a class=\"graphic graphic_picture graphicRef82130 \" href=\"UTD.htm?16/13/16592\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If you cannot advance the catheter, it has either been advanced too far through the posterior wall of the vein, or the needle entered the vein but the catheter did not. If you suspect the former situation, withdraw the needle slightly until you see a good blood flash in the hub, and then try advancing the catheter. If you suspect the latter situation, advance the needle slightly, and then try to advance the catheter. In many cases, you must abort the attempt at cannulation if these problems arise, and try a different site, proximal to the first if the same extremity is used.",
"     </li>",
"     <li>",
"      Occasionally, the catheter is in the lumen of the vein, but cannot be advanced because it lies against a valve or tortuous portion of the vein. If you suspect this, attach a syringe filled with isotonic saline to the catheter, and gently infuse fluid through the catheter while slowly advancing it. This problem can often be avoided by using relatively straight veins and by avoiding valves which are often visible as small, circumscribed bulges in the vein.",
"     </li>",
"     <li>",
"      If the IV catheter is appropriately placed, venous blood will flow steadily from the catheter, and no swelling will occur at the puncture site. Once the catheter has been inserted, push the button on the needle guard to allow the needle to be retracted and to prevent inadvertent needle stick injuries. Remove the tourniquet, secure the catheter, and attach the appropriate IV set up. If correctly placed, medicine or fluids should infuse easily, without pain or swelling at the catheter site (",
"      <a class=\"graphic graphic_picture graphicRef56946 \" href=\"UTD.htm?36/28/37315\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If swelling occurs and extravenous placement is suspected, remove the catheter, and apply pressure at the puncture site to reduce hematoma formation; then place a dressing over the puncture site.",
"     </li>",
"     <li>",
"      Inadvertent arterial catheter placement usually causes a pulsatile flow of bright red blood and produces an arterial wave form when a transducer is attached. If this occurs, remove the catheter and apply continuous pressure at the puncture site for approximately 10 minutes.",
"     </li>",
"     <li>",
"      When the procedure is completed, place all sharp objects in the proper container, and dispose of other materials appropriately (",
"      <a class=\"graphic graphic_picture graphicRef67731 \" href=\"UTD.htm?31/63/32752\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755169\">",
"    <span class=\"h2\">",
"     Ultrasound guided",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound has become a useful adjunct in the performance of many medical procedures, including placement of central and peripheral venous catheters. The use of ultrasound in the placement of peripheral venous catheters is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209581\">",
"    <span class=\"h1\">",
"     POST-PLACEMENT CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755176\">",
"    <span class=\"h2\">",
"     Securing the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the catheter is placed, secure it well to avoid dislodgement, which can cause extravasation of potentially harmful IV fluids and medications. In addition, movement of a poorly secured catheter may increase the risk of thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/48\">",
"     48",
"    </a>",
"    ]. If the IV catheter must be placed over a joint or in a dominant hand, it is often helpful to place a splint. Selection of an appropriate site for catheter placement is discussed above. (See",
"    <a class=\"local\" href=\"#H27755111\">",
"     'Site selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Peripheral catheters can be secured with tape, prefabricated adhesive dressings (eg, Opsite&trade;, Smith and Nephew, UK; Tegaderm&trade;, 3M, St. Paul, MN), suture, or specific IV securing devices. The relative advantages and disadvantages of these methods are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Site care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755183\">",
"    <span class=\"h2\">",
"     Maintaining patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral IV catheters placed for intermittent therapy (INT) require occasional flushing to keep them patent. This is not a concern when catheters are used for continuous infusions. Previously, dilute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    solutions were used to flush catheters, thus the term \"heparin lock.&rdquo; Multiple studies have found that periodic flushing with isotonic saline is equally effective in maintaining the patency of catheters used for INT, while avoiding heparin-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. No studies address the issue of how best to flush peripheral catheters with saline, but common practice is to use 2 to 10 mL of isotonic saline after any IV medication is given or every 4 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209609\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an IV has been successfully placed, clinicians should periodically reassess the catheter to verify proper placement and patency. Examine the site carefully if any redness, edema, pain, tenderness, or problems infusing develop. Ultrasound can be used to verify the catheter&rsquo;s position.",
"   </p>",
"   <p>",
"    Extravasation of fluid usually manifests as swelling and pain at the site and slow infusion rates. If IV fluids no longer infuse via gravity and the catheter cannot be flushed easily, a clot may have formed within the catheter. Do not flush the catheter forcefully because this can dislodge a clot into the circulation and should not be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755190\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed properly, peripheral IV placement is a safe procedure with little serious risk. Nevertheless, a number of potential complications have been described. Among the more common complications are phlebitis, extravasation of IV fluids, bruising, and hematoma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/14\">",
"     14",
"    </a>",
"    ]. Thrombophlebitis occurs in up to 15 percent of those with peripheral venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/55\">",
"     55",
"    </a>",
"    ]. This risk can be reduced by avoiding lower extremity IV placement, minimizing catheter movement, placing the smallest suitable catheter size, and removing the catheter as soon as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Catheters placed in emergency circumstances are more prone to complications.",
"   </p>",
"   <p>",
"    Peripheral venous catheters are thought to be rare causes of blood stream infections. The risk of infection from peripheral IV catheters and the practice of using a fixed schedule (eg, three days) to replace catheters are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly reported complications include septic discitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/59\">",
"     59",
"    </a>",
"    ], venous air embolism, pneumocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/60\">",
"     60",
"    </a>",
"    ], DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/61\">",
"     61",
"    </a>",
"    ], skin necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/62\">",
"     62",
"    </a>",
"    ], bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/63\">",
"     63",
"    </a>",
"    ], compartment syndrome, nerve injury, arterial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/64\">",
"     64",
"    </a>",
"    ], tendon injury, and venous aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6361/abstract/14,65\">",
"     14,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27755204\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV catheters should be placed when less invasive forms of therapy are not appropriate. &nbsp;",
"     </li>",
"     <li>",
"      Catheter selection varies according to the patient's condition and intended use. (See",
"      <a class=\"local\" href=\"#H2663520\">",
"       'Indications, contraindications, and difficulty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending upon clinical circumstances, we suggest using a local anesthetic prior to venipuncture. (See",
"      <a class=\"local\" href=\"#H27755147\">",
"       'Analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideally, peripheral IV catheters are placed in distal veins in the upper extremity. (See",
"      <a class=\"local\" href=\"#H27755111\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods to enhance venous dilation and successful cannulation are included in the text. (See",
"      <a class=\"local\" href=\"#H27755140\">",
"       'Vein dilation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27755162\">",
"       'Traditional percutaneous technique'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Localized pain or swelling or impaired infusate flow suggest a complication with the catheter, which should be carefully examined. (See",
"      <a class=\"local\" href=\"#H2209609\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27755190\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/1\">",
"      Sebbane M, Claret PG, Lefebvre S, et al. Predicting peripheral venous access difficulty in the emergency department using body mass index and a clinical evaluation of venous accessibility. J Emerg Med 2013; 44:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/2\">",
"      Juvin P, Blarel A, Bruno F, Desmonts JM. Is peripheral line placement more difficult in obese than in lean patients? Anesth Analg 2003; 96:1218, table of contents.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/3\">",
"      Jacobson AF, Winslow EH. Variables influencing intravenous catheter insertion difficulty and failure: an analysis of 339 intravenous catheter insertions. Heart Lung 2005; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     Adams, J. Intravenous and vascular access therapy. In: Clinical Nursing Skills and Techniques, Perry, AG, Potter, PA (Eds), Mosby, St. Louis 2006. p.898.",
"    </li>",
"    <li>",
"     Mulvey, MA. Fluid and electrolytes: balance and disturbance. In: Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 11th, Smeltzer, SC, Bare, BG, Hinkle, JL, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2008. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/6\">",
"      Crow S. Prevention of intravascular infections ways and means. J Intraven Nurs 1996; 19:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/7\">",
"      Sandhu NP, Sidhu DS. Mid-arm approach to basilic and cephalic vein cannulation using ultrasound guidance. Br J Anaesth 2004; 93:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/8\">",
"      Tager IB, Ginsberg MB, Ellis SE, et al. An epidemiologic study of the risks associated with peripheral intravenous catheters. Am J Epidemiol 1983; 118:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/9\">",
"      Clutton-Brock TH. Vascular access. How to set up a drip and keep it going. Br J Hosp Med 1984; 32:162, 164, 166.",
"     </a>",
"    </li>",
"    <li>",
"     Gray, H. Wrist and Hand. In: Gray's Anatomy: The Anatomical Basis of Clinical Practice, 39th, Standring, S, Ellis, H, Healy, JC (Eds), Church Livingstone, Philadelphia 2005. p.889.",
"    </li>",
"    <li>",
"     Moore, KL, Dalley, AF. Clinically Oriented Anatomy, 4th, Lippincott Williams and Wilkins, Philadelphia 1999. p.665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/12\">",
"      Kramer, DA, Staten-McCormick, M, Freeman, SB. Percutaneous brachial vein catheterization: an alternate site for intravenous access. [abstract 38]. Ann Emerg Med 1983; 12:247.",
"     </a>",
"    </li>",
"    <li>",
"     Agur, AM, Lee, MJ. Grant's Atlas of Anatomy, 9th, Williams and Wilkins, Baltimore 1991. p.549.",
"    </li>",
"    <li>",
"     Liu, SW, Zane, RD. Peripheral intravenous access. In: Clinical Procedures in Emergency Medicine, 4th, Roberts, JR, Hedges, JR (Eds), Saunders, Philadelphia 2004. p.401.",
"    </li>",
"    <li>",
"     Netter, FH. Atlast of Human Anatomy, 3rd, Icon Learning Systems, Teterboro 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/16\">",
"      Iserson KV. Is informed consent required for the administration of intravenous contrast and similar clinical procedures? Ann Emerg Med 2007; 49:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/17\">",
"      Scales K. Vascular access: a guide to peripheral venous cannulation. Nurs Stand 2005; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/18\">",
"      Pang CC. Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 2001; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/19\">",
"      Trimble T. Peripheral i.v. starts: securing and removing the catheter. Nursing 2003; 33:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/20\">",
"      Roberge RJ. Venodilatation techniques to enhance venepuncture and intravenous cannulation. J Emerg Med 2004; 27:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/21\">",
"      Mbamalu D, Banerjee A. Methods of obtaining peripheral venous access in difficult situations. Postgrad Med J 1999; 75:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/22\">",
"      Millam DA. Tips for improving your venipuncture techniques. Nursing 1987; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/23\">",
"      Hedges JR, Weinshenker E, Dirksing R. Evaluation of venous distension device: potential aid for intravenous cannulation. Ann Emerg Med 1986; 15:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/24\">",
"      Kindgen-Milles D, Arndt JO. Nitric oxide as a chemical link in the generation of pain from veins in humans. Pain 1996; 64:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/25\">",
"      Campbell J. Making sense of the technique of venepuncture. Nurs Times 1995; 91:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/26\">",
"      Lenhardt R, Seybold T, Kimberger O, et al. Local warming and insertion of peripheral venous cannulas: single blinded prospective randomised controlled trial and single blinded randomised crossover trial. BMJ 2002; 325:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/27\">",
"      Beer J. Local warming does help when inserting cannulas. BMJ 2002; 325:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/28\">",
"      Roberts GH, Carson J. Venipuncture tips for radiologic technologists. Radiol Technol 1993; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/29\">",
"      Datta S, Hanning CD. How to insert a peripheral venous cannula. Br J Hosp Med 1990; 43:67.",
"     </a>",
"    </li>",
"    <li>",
"     Graza, D, Becan-Mcbride, K. Phlebotomy Handbook, Appleton and Lange, Stamford 1996. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/31\">",
"      Moureau NL. Tips for inserting an i.v. in an older patient. Nursing 2004; 34:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/32\">",
"      Murray WB. The reverse Esmarch bandage for venous access. S Afr Med J 1993; 83:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/33\">",
"      Roberge RJ, Kelly M, Evans TC, et al. Facilitated intravenous access through local application of nitroglycerin ointment. Ann Emerg Med 1987; 16:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/34\">",
"      Stein JI. A new technique for obtaining large-bore peripheral intravenous access. Anesthesiology 2005; 103:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/35\">",
"      Krueger A. Need help finding a vein? Nursing 2007; 37:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/36\">",
"      Whiteley MS, Chang BY, Marsh HP, et al. Use of hand-held Doppler to identify 'difficult' forearm veins for cannulation. Ann R Coll Surg Engl 1995; 77:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/37\">",
"      Sado DM, Deakin CD. Local anaesthesia for venous cannulation and arterial blood gas sampling: are doctors using it? J R Soc Med 2005; 98:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/38\">",
"      McNaughton C, Zhou C, Robert L, et al. A randomized, crossover comparison of injected buffered lidocaine, lidocaine cream, and no analgesia for peripheral intravenous cannula insertion. Ann Emerg Med 2009; 54:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/39\">",
"      Langham BT, Harrison DA. Local anaesthetic: does it really reduce the pain of insertion of all sizes of venous cannula? Anaesthesia 1992; 47:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/40\">",
"      Harrison N, Langham BT, Bogod DG. Appropriate use of local anaesthetic for venous cannulation. Anaesthesia 1992; 47:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/41\">",
"      Kundu S, Achar S. Principles of office anesthesia: part II. Topical anesthesia. Am Fam Physician 2002; 66:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/42\">",
"      Brown J, Larson M. Pain during insertion of peripheral intravenous catheters with and without intradermal lidocaine. Clin Nurse Spec 1999; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/43\">",
"      Smith DW, Peterson MR, DeBerard SC. Local anesthesia. Topical application, local infiltration, and field block. Postgrad Med 1999; 106:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/44\">",
"      Eidelman A, Weiss JM, Lau J, Carr DB. Topical anesthetics for dermal instrumentation: a systematic review of randomized, controlled trials. Ann Emerg Med 2005; 46:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/45\">",
"      Singer AJ, Homan CS, Church AL, McClain SA. Low-frequency sonophoresis: pathologic and thermal effects in dogs. Acad Emerg Med 1998; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/46\">",
"      Becker BM, Helfrich S, Baker E, et al. Ultrasound with topical anesthetic rapidly decreases pain of intravenous cannulation. Acad Emerg Med 2005; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/47\">",
"      Singer AJ, Regev R, Weeks R, Tlockowski DS. Laser-assisted anesthesia prior to intravenous cannulation in volunteers: a randomized, controlled trial. Acad Emerg Med 2005; 12:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/48\">",
"      Sheppard K, LeDesma M, Morris NL, O'Connor K. A prospective study of two intravenous catheter securement techniques in a skilled nursing facility. J Intraven Nurs 1999; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/49\">",
"      Dougherty L. Reducing the risk of complications in i.v. therapy. Nurs Stand 1997; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/50\">",
"      Goode CJ, Titler M, Rakel B, et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res 1991; 40:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/51\">",
"      Dunn DL, Lenihan SF. The case for the saline flush. Am J Nurs 1987; 87:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/52\">",
"      Maki DG, Botticelli JT, LeRoy ML, Thielke TS. Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective. JAMA 1987; 258:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/53\">",
"      Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ 1998; 316:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/54\">",
"      Fernandez RS, Griffiths RD, Murie P. Peripheral venous catheters: a review of current practices. J Infus Nurs 2003; 26:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/55\">",
"      Monreal M, Oller B, Rodriguez N, et al. Infusion phlebitis in post-operative patients: when and why. Haemostasis 1999; 29:247.",
"     </a>",
"    </li>",
"    <li>",
"     Weinstein, SM. Plumer's Principles and Practice of Intravenous Therapy, 7th, Lippincott Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/57\">",
"      Haddad FG, Waked CH, Zein EF. Peripheral venous catheter-related inflammation. A randomized prospective trial. J Med Liban 2006; 54:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/58\">",
"      Singh R, Bhandary S, Pun KD. Peripheral intravenous catheter related phlebitis and its contributing factors among adult population at KU Teaching Hospital. Kathmandu Univ Med J (KUMJ) 2008; 6:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/59\">",
"      Greig JM, Ellis CJ, Smith EG. Septic discitis and other complications of peripheral venous cannulation. QJM 2002; 95:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/60\">",
"      Yildiz A, Ozer C, Egilmez H, et al. Iatrogenic intravascular pneumocephalus secondary to intravenous catheterization. Eur Radiol 2002; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/61\">",
"      Dubois J, Rypens F, Garel L, et al. Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents. CMAJ 2007; 177:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/62\">",
"      Kagel EM, Rayan GM. Intravenous catheter complications in the hand and forearm. J Trauma 2004; 56:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/63\">",
"      Pujol M, Hornero A, Saballs M, et al. Clinical epidemiology and outcomes of peripheral venous catheter-related bloodstream infections at a university-affiliated hospital. J Hosp Infect 2007; 67:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/64\">",
"      Lirk P, Keller C, Colvin J, et al. Unintentional arterial puncture during cephalic vein cannulation: case report and anatomical study. Br J Anaesth 2004; 92:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6361/abstract/65\">",
"      Debnath D, Wallace S, Mylona E, Myint F. Aneurysm of antecubital vein: an unusual complication of peripheral intravenous cannulation. BMC Surg 2007; 7:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13824 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6361=[""].join("\n");
var outline_f6_13_6361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27755204\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755068\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2663520\">",
"      INDICATIONS, CONTRAINDICATIONS, AND DIFFICULTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755075\">",
"      Indications for venous access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755089\">",
"      Indications for peripheral versus central venous access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15275188\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52513128\">",
"      Anticipated difficulty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755096\">",
"      MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755104\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209344\">",
"      Catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755111\">",
"      SITE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209385\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209392\">",
"      Anatomy and vein selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755118\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755126\">",
"      Consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755133\">",
"      Basic preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209949\">",
"      Prevention of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755140\">",
"      Vein dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2663664\">",
"      Tools for locating veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755147\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755154\">",
"      CATHETER INSERTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755162\">",
"      Traditional percutaneous technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755169\">",
"      Ultrasound guided",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2209581\">",
"      POST-PLACEMENT CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755176\">",
"      Securing the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27755183\">",
"      Maintaining patency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209609\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755190\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27755204\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13824|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/15/44281\" title=\"figure 1\">",
"      Superficial veins of hand and forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/3/18480\" title=\"figure 2\">",
"      Anterior view superficial veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/3/42038\" title=\"figure 3\">",
"      Superficial veins of neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17210\" title=\"figure 4\">",
"      Veins of leg and foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13824|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/12/23751\" title=\"picture 1\">",
"      Peripheral IV catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/25/35217\" title=\"picture 2\">",
"      Peripheral IV placement 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/55/32624\" title=\"picture 3\">",
"      Peripheral IV placement 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/3/10289\" title=\"picture 4\">",
"      Peripheral IV placement 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/45/3793\" title=\"picture 5\">",
"      Peripheral IV placement 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/13/16592\" title=\"picture 6\">",
"      Peripheral IV placement 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/28/37315\" title=\"picture 7\">",
"      Peripheral IV placement 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/63/32752\" title=\"picture 8\">",
"      Peripheral IV placement 8",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=related_link\">",
"      Placement of jugular venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=related_link\">",
"      Placement of subclavian venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6362="Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia";
var content_f6_13_6362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/13/6362/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/13/6362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5623314\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas. The term CLL is used when the disease manifests primarily in the bone marrow and blood, whereas the term SLL is used when involvement is primarily nodal. While there is some difference to the treatment of early stage CLL and SLL, the treatment of advanced stage disease is the same. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of initial therapy for advanced stage or symptomatic disease will be reviewed here. General issues regarding the treatment of",
"    <span class=\"nowrap\">",
"     CLL/SLL,",
"    </span>",
"    the treatment of",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    CLL, the use of hematopoietic cell transplantation in CLL, and the management of complications of CLL and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, diagnosis, staging, and prognosis of CLL and SLL are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5622415\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1664568\">",
"    <span class=\"h2\">",
"     Our general approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreed upon standard treatment regimen for symptomatic CLL or advanced SLL. Experts in the field use different treatment approaches. As such, there are several initial treatment options for patients with symptomatic CLL or advanced SLL. These include purine analogs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ), alkylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    ), monoclonal antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ), or combinations of these agents. The optimal therapy for each of the subpopulations of CLL patients (eg, young, elderly, or patients with high-risk features) is not currently known, and is the subject of multiple ongoing cooperative studies. The best treatment for an individual patient may be enrollment in a well-conducted clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Investigational therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the treatment options have not been directly compared. When prospective randomized trials have been performed, most regimens have been compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , an alkylating agent that had been a standard of care for decades prior to the advent of newer agents (eg, monoclonal antibodies, purine analogs). The estimated median overall survival with modern regimens is approximately five years. While overall survival rates are similar, these regimens differ in their rates of complete remission (CR), time to progression, and associated toxicities. For patients who do not wish to participate in a clinical trial, our choice among these therapies is made based upon patient characteristics, tumor characteristics, and goals of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most younger (&lt;70 years) patients, we prefer the use of a regimen that contains both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Specifically, we use combination therapy with either fludarabine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and rituximab (FCR) (",
"      <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"       table 1",
"      </a>",
"      ) or fludarabine plus rituximab (FR) (",
"      <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"       table 2",
"      </a>",
"      ). As described in more detail below, studies suggest that regimens that include these agents improve survival in this patient population. (See",
"      <a class=\"local\" href=\"#H23868573\">",
"       'Choice of fludarabine regimen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For most older adults (&gt;70 years) with CLL, we prefer initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      . While",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based therapy results in superior response rates, it does not appear to improve survival in this population. In addition, older patients who have a compromised performance status may have a higher incidence of opportunistic infections with fludarabine-based therapy. Fludarabine may also lead to prolonged myelosuppression in this age group. (See",
"      <a class=\"local\" href=\"#H5624031\">",
"       'Older adults'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with del(17p) or del(11q) are at high risk of either not responding to initial treatment, or relapsing soon after achieving remission and should be encouraged to participate in clinical trials. For these patients, we prefer initial treatment with FCR, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      . Younger patients with an HLA-matched related or matched unrelated donor are considered for non-myeloablative allogeneic hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H5624038\">",
"       'High-risk disease: del(17p) or del(11q)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5622422\">",
"    <span class=\"h2\">",
"     Fludarabine-based therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23868573\">",
"    <span class=\"h3\">",
"     Choice of fludarabine regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preferred first line therapy for most patients with CLL is combination therapy that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Long-term toxicity with fludarabine-based regimens appears to be limited to myelotoxicity and infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/1\">",
"     1",
"    </a>",
"    ]. The use of fludarabine also increases the rate of development of autoimmune hemolytic anemia. The addition of rituximab to initial therapy has been associated with improved survival in younger patients with CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link\">",
"     \"Autoimmune complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FCR) (",
"      <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FR) (",
"      <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial comparing FCR and FR is underway in the US intergroup (CALGB 10404). In phase II trials, overall survival rates appear to be similar with these regimens, but toxicity is lower with FR. FCR appears to result in higher complete remission rates (70 versus 47 percent), but similar overall response rates (95 versus 90 percent). The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and the human CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    (O-FC) has demonstrated activity in previously untreated CLL, but long-term results with this regimen and comparative trials are unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FCR appears to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (FC). An open-label, phase III randomized trial compared six courses of FCR with six courses of FC in 817 previously untreated patients with CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. FCR resulted in the following statistically significant findings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher rates of overall (95 versus 88 percent) and complete (44 versus 22 percent) response",
"     </li>",
"     <li>",
"      Longer median progression-free survival (52 versus 33 months)",
"     </li>",
"     <li>",
"      Better overall survival at three years (87 versus 83 percent)",
"     </li>",
"     <li>",
"      Higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (34 versus 21 percent), leukocytopenia (24 versus 12 percent)",
"     </li>",
"     <li>",
"      Similar rates of treatment-related deaths (2 versus 3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    -based therapy has also demonstrated superiority to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    in younger adults. Several prospective, randomized trials comparing single agent purine analogs (eg, fludarabine) to alkylating agents (eg, chlorambucil) demonstrated improved response rates and progression-free survival for patients treated with purine analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/7\">",
"     7",
"    </a>",
"    ]. While initial reports demonstrated similar survival rates, long-term follow-up of a randomized phase III trial comparing fludarabine, chlorambucil, or a combination of the two in 509 previously untreated patients with CLL demonstrated that, when compared with chlorambucil alone, single agent fludarabine results in significantly higher overall survival rates at six years (43 versus 38 percent) and at eight years (31 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/8\">",
"     8",
"    </a>",
"    ]. A separate analysis of 663 patients enrolled onto successive trials of initial therapy in CLL confirmed a survival benefit for fludarabine compared with chlorambucil among patients younger than 70 years (hazard ratio [HR] 0.7, 95% CI 0.5-0.9), but not in those over 70 years (HR 1.0, 95% CI 0.6-1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data from long-term analyses show that the drug chosen for the initial treatment can be important and may manifest its survival benefit over another drug only several years later. In addition, they demonstrate the importance of patient characteristics (eg, age) on the choice of therapy. (See",
"    <a class=\"local\" href=\"#H5624031\">",
"     'Older adults'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5622436\">",
"    <span class=\"h3\">",
"     Fludarabine, cyclophosphamide, and rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;FCR is our preferred treatment option for younger patients (&lt;70 years) with standard risk CLL. Several nonrandomized phase II trials have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (FCR) in previously untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. In addition, the randomized trial described above demonstrated superior survival rates with FCR when compared with fludarabine plus cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/6\">",
"     6",
"    </a>",
"    ]. The FCR regimen has been administered in different variations (",
"    <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5622422\">",
"     'Fludarabine-based therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Overall response and CR rates with FCR are approximately 95 and 70 percent, respectively. At the time the largest of these studies were performed, CR did not require negative flow cytometry of the peripheral blood. However, most patients with CR had no detectable disease on flow cytometry at the end of therapy suggesting a potentially deeper response. The estimated four-year failure-free survival is 69 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Six-year follow-up is available for 300 patients initially treated with FCR combination therapy as part of one of these prospective phase II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/15\">",
"     15",
"    </a>",
"    ]. Six-year overall and failure-free survival rates were 77 and 51 percent, respectively, and the median time to progression was 80 months. The risk of late infection for the first and second years were 10 and 4 percent with rates of &lt;1.5 percent per year for subsequent years.",
"   </p>",
"   <p>",
"    Treatment-related mortality was less than 1 percent. The first dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was associated with infusional symptoms (fever, chills, hypotension, dyspnea, nausea, or vomiting) that were usually mild and responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    therapy. Subsequent infusions of rituximab were usually uneventful. Additional toxicities with FCR included cytopenias, infections, nausea (23 percent), vomiting (7 percent), and hair loss. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia occurred in 52 percent, but major or minor infections occurred in only 2.6 and 10 percent of cycles, respectively.",
"   </p>",
"   <p>",
"    Less common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    can include hemorrhagic cystitis, bladder carcinogenesis, impairment of fertility, leukemogenesis, and, with prolonged high dose therapy, interstitial pulmonary fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data are available for a regimen that adds",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    to the FCR combination (R-FCM). A phase II trial of R-FCM followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    maintenance in 72 previously untreated patients with CLL reported overall and complete response rates of 93 and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/16\">",
"     16",
"    </a>",
"    ]. We await longer follow-up and additional reports confirming these results prior to incorporating this regimen into our initial therapy of patients with CLL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23868398\">",
"    <span class=\"h3\">",
"     Fludarabine plus rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (FR) is an acceptable alternative to FCR as the initial treatment of younger adults (&lt;70 years) with standard risk CLL. FR has been studied both prospectively in varying dosing schedules and retrospectively compared with fludarabine treatment alone. Concurrent administration results in higher response rates and moderately higher toxicity when compared with sequential therapy. The concurrent administration of fludarabine plus rituximab results in overall response and CR rates of approximately 90 and 47 percent, respectively. The administration of FR to patients with CLL can be complicated by infusion-related reactions and tumor lysis syndrome. Several variations on administration dose and schedule have been used (",
"    <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A randomized phase II trial evaluated concurrent or sequential FR in 104 symptomatic, previously untreated patients with CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/17\">",
"     17",
"    </a>",
"    ]. The concurrent arm received induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in six 28-day cycles followed by consolidation rituximab for responders. The sequential arm received induction with fludarabine alone in six 28-day cycles followed by consolidation rituximab for responders. Although the treatment was randomly assigned, the study was not designed for the direct comparison of response rates in the two arms. Overall response rates for the concurrent and sequential treatment arms were 90 percent (47 percent CR) and 77 percent (28 percent CR), respectively. At a median follow-up of 117 months, the median overall survival was 85 months with a five-year survival rate of 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/18\">",
"     18",
"    </a>",
"    ]. The median progression-free survival (PFS) was 42 months with a five-year PFS rate of 27 percent. The estimated PFS at 10 years was 13 percent.",
"   </p>",
"   <p>",
"    Neutropenia and infusion-related toxicities were more common in patients receiving concurrent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients treated with concurrent FR had a significantly higher rate of severe neutropenia (76 versus 39 percent) when compared with patients who received sequential therapy, but a similar rate of severe infection (approximately 20 percent). Infusion-related toxicity was usually mild and was seen in all patients given concordant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . After a median follow-up of 117 months, no patient developed therapy-related myelodysplastic syndrome (t-MDS) or acute myeloid leukemia while in remission following FR alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/18\">",
"     18",
"    </a>",
"    ]. One patient who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and rituximab (FCR) for the treatment of relapsed CLL later developed t-MDS. Four patients underwent Richter&rsquo;s transformation to a more aggressive lymphoma.",
"   </p>",
"   <p>",
"    A retrospective analysis comparing treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    alone (fludarabine arm, CALGB 9011) to treatment with fludarabine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (CALGB 9712) indicated better progression-free and overall survival rates with the two-drug combination, with similar infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23868301\">",
"    <span class=\"h2\">",
"     Bendamustine-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    has received approval from the US Food and Drug Administration for both previously untreated as well as relapsed CLL. Bendamustine has demonstrated superior response rates when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    . However, a survival benefit has not been demonstrated. Single arm studies have demonstrated higher response rates when bendamustine is administered in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (BR). This BR regimen is preferred to single agent bendamustine based upon analyses that have demonstrated superior survival when rituximab is added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy in CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large, multi-institutional randomized clinical study demonstrated superior response rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    therapy. In this trial of 319 patients with previously untreated and symptomatic CLL, treatment was randomly assigned either with chlorambucil or with bendamustine for up to six cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/20\">",
"     20",
"    </a>",
"    ]. Bendamustine was given at a dose of 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over 30 minutes on days 1 and 2 of a 28-day cycle. The trial excluded patients with autoimmune hemolytic anemia, autoimmune thrombocytopenia, Richter's syndrome, or transformation to prolymphocytic leukemia. Patients who were treated with bendamustine had significantly higher rates of overall response (68 versus 31 percent) and longer median progression-free survival (21.6 versus 8.3 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall survival data show no difference between these two arms, but require longer follow-up. Patients assigned to therapy with bendamustine had a trend towards more severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities including: neutropenia (23 versus 10 percent), thrombocytopenia (12 versus 8 percent), and anemia (3 versus zero percent). In addition, bendamustine use was associated with hypersensitivity reactions (5 versus 2 percent) and gastrointestinal toxicities requiring more frequent use of antiemetics (36 versus 4 percent).",
"   </p>",
"   <p>",
"    The BR regimen was evaluated in a single arm trial of 117 patients (age 34 to 78 years) with previously untreated CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/22\">",
"     22",
"    </a>",
"    ]. The regimen consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 2 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 0 of the first course and 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 of subsequent courses. Patients received up to six courses. The overall and complete response rates were 88 and 23 percent, respectively, and included patients with high risk disease. After a median follow-up of 27 months, the median event-free survival was 34 months. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included neutropenia (20 percent), thrombocytopenia (22 percent), anemia (20 percent), and infections (8 percent).",
"   </p>",
"   <p>",
"    An ongoing large prospective randomized trial is comparing FCR with BR as initial therapy for patients with previously untreated CLL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23868177\">",
"    <span class=\"h2\">",
"     Pentostatin-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    is a purine analog that has been used for the treatment of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. Combination therapy is preferred to single agent therapy because it results in superior complete response rates and treatment-free survival rates in phase II trials.",
"   </p>",
"   <p>",
"    The most commonly used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    -based regimens consist of pentostatin (2 to 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    given intravenously in 21-day cycles (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase II trial in 64 patients (median age 63 years) with previously untreated symptomatic CLL evaluated the use of PCR every 21 days for six planned cycles with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) support [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/23\">",
"     23",
"    </a>",
"    ]. Overall and complete response rates were 91 and 41 percent, respectively. The rates of severe (grade 3 or higher) hematologic and nonhematologic toxicity were 52 and 34 percent, respectively. The most common nonhematologic toxicities were infection (9 percent), nausea (9 percent), vomiting (6 percent), and fever (6 percent). There were two deaths during treatment.",
"   </p>",
"   <p>",
"    Some clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    -based therapy for its ease of administration and initial reports of less myelosuppression when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy. However, many of the prospective trials of pentostatin-based regimens have included the use of hematopoietic growth factors for all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23869242\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Front-line therapy with the anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    has demonstrated superior response rates when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    . However, a survival benefit has not been demonstrated. The manufacturer of alemtuzumab withdrew this product from the US market in September 2012. These actions were not related to safety concerns, but instead were to prepare for the planned marketing of this drug under a different name for other conditions. Alemtuzumab remains accessible through a distribution program for the treatment of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/29\">",
"     29",
"    </a>",
"    ]. For most patients with previously untreated CLL, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy to alemtuzumab except in the initial treatment of patients with chromosome 17p deletion. (See",
"    <a class=\"local\" href=\"#H5624038\">",
"     'High-risk disease: del(17p) or del(11q)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    results in overall response and complete remission (CR) rates of approximately 83 and 24 percent, respectively. Alemtuzumab has been least effective in patients with bulky lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. As an example, a study in previously treated patients found that overall response rates with alemtuzumab varied greatly depending upon the size of enlarged nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/33\">",
"     33",
"    </a>",
"    ]. Overall response rates were 87, 40, and 9 percent in patients with no lymphadenopathy, those whose largest node was &le;5 cm, and those whose largest node was &gt;5 cm, respectively. Common toxicities of alemtuzumab include neutropenia, infections, and infusion reactions.",
"   </p>",
"   <p>",
"    A prospective phase III trial of 297 previously untreated, symptomatic patients with Rai stage I-IV CLL randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (30 mg IV over two hours three",
"    <span class=\"nowrap\">",
"     times/week",
"    </span>",
"    on alternate days for a maximum of 12 weeks) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    PO once every 28 days for a maximum of 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/34\">",
"     34",
"    </a>",
"    ]. Most patients (77 percent) had maximum lymph nodes &lt;5 cm in diameter. World Health Organization performance status was zero or one in 96 percent.",
"   </p>",
"   <p>",
"    All patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    were given prophylactic antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    DS) and antiviral agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) during therapy and until CD4+ cell counts were",
"    <span class=\"nowrap\">",
"     &ge;200/microL",
"    </span>",
"    and for a minimum of two months after last treatment.",
"   </p>",
"   <p>",
"    At a median follow-up of 25 months, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    had the following significantly better outcomes when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher overall response (83 versus 55 percent) and complete remission (24 versus 2 percent) rates",
"     </li>",
"     <li>",
"      Longer progression-free survival (15 versus 12 months) and time to alternative treatment (23 versus 15 months)",
"     </li>",
"     <li>",
"      Higher response rate in patients with 17p deletion (64 versus 20 percent), as noted in a subset analysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The study was not powered to find a difference in overall survival.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    therapy was associated with higher rates of the following toxicities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia (41 versus 25 percent). The rates of febrile neutropenia (5 versus 3 percent) and",
"      <span class=\"nowrap\">",
"       bacteremia/sepsis",
"      </span>",
"      (3 versus 1.5 percent) were similar.",
"     </li>",
"     <li>",
"      Symptomatic CMV infections (16 versus zero percent) and CMV viremia (56 versus 8 percent).",
"     </li>",
"     <li>",
"      Infusion reaction that included fevers (69 percent), chills (53 percent), nausea (18 percent), hypotension (16 percent), urticaria (16 percent), headache (14 percent), dyspnea (14 percent), and vomiting (11 percent). Less common infusion reactions included tachycardia, anxiety, pruritus, tremor, and bronchospasm. These side effects appear to be less when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      is administered subcutaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the concurrent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    plus a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based combination has been associated with high response rates, wide application of these combinations is limited by unacceptably high rates of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The use of alemtuzumab consolidation following initial treatment with a fludarabine-based combination may be better tolerated, but the efficacy and the best scheduling remain to be determined. (See",
"    <a class=\"local\" href=\"#H5624038\">",
"     'High-risk disease: del(17p) or del(11q)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5624009\">",
"    <span class=\"h1\">",
"     SPECIAL PATIENT POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most patients with symptomatic or advanced stage CLL are treated similarly, older patients and patients with del(17p) or del(11q) require particular consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5624031\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns about the ability of older adults (ie, over age 70 years) to tolerate chemotherapy. The management of CLL in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in such patients, thereby permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in older adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options for older adults with CLL who might have varying levels of co-morbidities and compromised performance status, in order of increasing response rates and increasing toxicity, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulsed intermittent single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      (eg, a single oral dose of 0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks, adjusted as needed)",
"     </li>",
"     <li>",
"      Lower dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV for three consecutive days every month)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FR) (",
"      <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FCR) (",
"      <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For older adults with CLL, we prefer initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    . This preference is based upon the better tolerability of chlorambucil and similar survival rates when compared with other agents in this population.",
"   </p>",
"   <p>",
"    A phase III trial included 193 older adults (median age 70) with an adequate performance status (Eastern Cooperative Oncology Group 2 or better), and symptomatic, previously untreated CLL who were randomly assigned to single agent treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/38\">",
"     38",
"    </a>",
"    ]. After a median follow-up of 42 months, patients assigned to chlorambucil had the following outcomes when compared with those assigned to fludarabine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly lower rates of overall (51 versus 72 percent) and complete (zero versus 7 percent) response.",
"     </li>",
"     <li>",
"      Similar rates of progression-free survival (18 versus 19 months), a nonsignificant trend toward longer overall survival with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      (64 versus 46 months), and a significantly higher proportion of patients who were retreated with either chlorambucil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      for disease progression (77 versus 50 percent).",
"     </li>",
"     <li>",
"      Lower rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      myelotoxicity (23 versus 42 percent), but similar rates of severe infection (4 versus 8 percent) and all infections (32 versus 26 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, an analysis of 663 patients enrolled onto successive trials of initial therapy in CLL demonstrated a survival benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    among patients younger than 70 years (hazard ratio [HR] 0.7, 95% CI 0.5 to 0.9), but not in those over 70 years (HR 1.0, 95% CI 0.6 to 1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/2\">",
"     2",
"    </a>",
"    ]. Together, these studies suggest that the outcomes after initial therapy differ with age. While fludarabine-based therapy results in superior response rates, a survival benefit compared to single agent chlorambucil therapy has yet to be confirmed in this older population.",
"   </p>",
"   <p>",
"    We give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    in a pulsed intermittent dose schedule (eg, a single oral dose of 0.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks). The chlorambucil dose is modified based upon laboratory studies to prevent the development of significant anemia, neutropenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia, which are the main toxicities associated with its use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/39\">",
"     39",
"    </a>",
"    ]. Other less common adverse effects of chlorambucil include infertility, seizures, hepatotoxicity, hypersensitivity, drug fever, pulmonary fibrosis, and interstitial pneumonia.",
"   </p>",
"   <p>",
"    An acceptable alternative for older adults with a good performance status (ECOG &le;2) is treatment with FR or FCR. This option may be preferred by those who are willing to accept the increased toxicity associated with these regimens and place a high value on the potential for a deeper response. The median age at diagnosis of CLL is 70 years, and many of the prospective trials described above that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy have included older patients with a good performance status. Fludarabine-based combination chemotherapy regimens can be delivered safely to older patients who have a good performance status with modestly increased myelosuppression but no increase in severe infectious complications or treatment-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/40\">",
"     40",
"    </a>",
"    ]. Cumulative myelosuppression has been noted with FCR, and older patients, in particular, may not be able to tolerate six courses. A regimen labeled &ldquo;FCR-lite&rdquo; has been described, which has a higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , but somewhat lower doses of fludarabine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/11\">",
"     11",
"    </a>",
"    ]. We do not advocate the use of this regimen until further data are obtained comparing it with other available treatments.",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to initial therapy has been associated with improved survival in younger patients with CLL. An observational study of 2040 older adults (&gt;65 years) with CLL who initiated infusional therapy reported superior outcomes among patients who received rituximab plus chemotherapy when compared with those who received chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/41\">",
"     41",
"    </a>",
"    ]. Another analysis of 663 patients with previously untreated CLL enrolled on successive phase II and III CALGB trials demonstrated that the benefit obtained from rituximab was similar in younger and older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, we incorporate rituximab into the treatment of older adults with CLL and a good performance status who select treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimen (ie, FCR or FR). (See",
"    <a class=\"local\" href=\"#H23868573\">",
"     'Choice of fludarabine regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An alternative treatment option for older adults with poor performance status is lower dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV for three consecutive days every month). In the US, the oral formulation of fludarabine is also approved by the FDA, but it has not yet been in widespread use. The recommended dosage is 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for five consecutive days every month for up to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5624038\">",
"    <span class=\"h2\">",
"     High-risk disease: del(17p) or del(11q)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with del(17p) or del(11q) are at high risk of either not responding to initial treatment, or relapsing soon after achieving remission. As an example, one study reported median survival rates are approximately 3, 7, and 11 years for patients with del(17p), del(11q), or normal cytogenetics, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/42\">",
"     42",
"    </a>",
"    ]. At the time of initial diagnosis, these patients should be referred to a transplant center for evaluation for possible allogeneic hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appropriate treatment for these patients remains undefined at this time. These patients should be encouraged to enroll in clinical trials, whenever possible. Treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      combinations (eg, fludarabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , FCR), followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , either after a number of cycles of initial debulking chemotherapy, or at the time of relapse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"     </li>",
"     <li>",
"      Consideration of non-myeloablative allogeneic hematopoietic cell transplantation (HCT) for younger patients with a matched related or matched unrelated donor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"       \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    is the only FDA-approved agent that has demonstrated activity in cells lacking p53 function, as seen in patients with CLL and chromosome 17p deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. As such, we and others advocate the incorporation of alemtuzumab into the treatment of patients with del(17p) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    appears to be less toxic when administered as consolidation therapy following initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy than when administered concurrently with other therapies. As such, we typically administer FCR followed by alemtuzumab therapy and referral for possible non-myeloablative allogeneic HCT. The following is a selection of prospective trials that have evaluated the use of alemtuzumab consolidation after fludarabine-based therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, randomized phase III trial also evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      consolidation after complete or partial remission with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/47\">",
"       47",
"      </a>",
"      ]. This trial was stopped prematurely after enrollment of 21 patients due to severe infections (cytomegalovirus reactivations and pulmonary aspergillosis) in more than half of the patients treated with alemtuzumab. However, when the results of all the patients who had been entered in the study were analyzed, it was noted that after a median follow-up of 48 months, patients who received alemtuzumab consolidation had significantly higher rates of three-year progression-free survival (82 versus 30 percent) when compared with those who did not receive alemtuzumab.",
"     </li>",
"     <li>",
"      A prospective, single-arm trial evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FR) followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      therapy for 41 previously untreated patients with CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/48\">",
"       48",
"      </a>",
"      ]. This regimen was poorly tolerated with only half of the enrolled patients completing the intended therapy mostly related to infectious complications or infusion reactions with alemtuzumab.",
"     </li>",
"     <li>",
"      A prospective trial evaluated six cycles of FR followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      therapy in 102 patients with previously untreated symptomatic CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/49\">",
"       49",
"      </a>",
"      ]. While consolidation with alemtuzumab deepened the responses initially seen with FR, it was associated with serious infections and five infection-related deaths, which occurred up to seven months after last therapy. Therefore, this combination cannot be recommended outside of a carefully monitored clinical trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multicenter phase II trial, 17 previously untreated and 22 previously treated patients with CLL lacking p53 function received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (30 mg three times a week) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five consecutive days) administered every four weeks for up to 16 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/13/6362/abstract/50\">",
"     50",
"    </a>",
"    ]. All patients received antimicrobial prophylaxis with cotrimoxazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    ). On subset analysis of previously untreated patients, overall and complete responses were seen in 15 patients (88 percent) and 11 patients (65 percent), respectively. Median progression-free and overall survivals were 11.8 and 23.5 months, respectively. Treatment-related mortality was 5 percent. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities were neutropenia (64 percent), infection (51 percent), thrombocytopenia (31 percent), anemia (31 percent), and glucocorticoid-associated toxicity (23 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623578\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders and is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H1#H1\">",
"       \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CLL is an extremely heterogeneous disease and not all patients require treatment at the time of diagnosis. Therapy is indicated for patients with advanced stage disease, high tumor burden, severe disease-related \"B\" symptoms, or repeated infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Indications for treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior to the initiation of active therapy for patients with symptomatic disease, patients with CLL should undergo a pre-treatment evaluation to determine the extent of disease, patient performance status, and assessment of comorbidities that are likely to have an impact on treatment options. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H5625565#H5625565\">",
"       \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Pre-treatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no agreed upon standard front-line treatment regimen for symptomatic CLL or advanced SLL. There are several initial treatment options for patients with symptomatic CLL or advanced SLL. Most have not been directly compared. While overall survival rates with the different available regimens are similar, they differ in their rates of complete remission (CR), time to progression, and associated toxicities. A choice between these therapies is made based upon patient characteristics and goals of therapy. Median overall survival with each of these regimens is approximately five years. (See",
"      <a class=\"local\" href=\"#H5622415\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based therapies rather than more recently approved agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Specifically, we use combination therapy with either fludarabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FR) (",
"      <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"       table 2",
"      </a>",
"      ) or fludarabine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and rituximab (FCR) (",
"      <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5622422\">",
"       'Fludarabine-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      FR results in overall response and CR rates of approximately 90 and 47 percent, respectively. The administration of FR to patients with CLL can be complicated by infusion-related reactions and tumor lysis syndrome. Several variations on dose and schedule have been used. (See",
"      <a class=\"local\" href=\"#H23868398\">",
"       'Fludarabine plus rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FCR results in overall response and CR rates of approximately 95 and 70 percent, respectively. CR achieved with FCR appears to be \"deeper\" with frequent cases demonstrating no detectable disease on flow cytometry. The FCR regimen has been administered in different variations. (See",
"      <a class=\"local\" href=\"#H5622436\">",
"       'Fludarabine, cyclophosphamide, and rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      have been compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      in prospective, randomized trials that have demonstrated superior response rates with the newer agents. No survival benefits have been noted and these agents have not been compared directly with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based therapy. (See",
"      <a class=\"local\" href=\"#H23869242\">",
"       'Alemtuzumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23868301\">",
"       'Bendamustine-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      While most patients with symptomatic or advanced stage CLL are treated similarly, older patients (&gt;60 years) and patients with del(17p) or del(11q) require particular consideration:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For older adults with symptomatic CLL, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      or other agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5624031\">",
"       'Older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with del(17p) or del(11q) are at high risk of either not responding to initial treatment, or relapsing soon after achieving remission and should be encouraged to participate in clinical trials. For these patients, we suggest initial treatment with FCR, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Younger patients with a matched related or matched unrelated donor are considered for non-myeloablative allogeneic hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H5624038\">",
"       'High-risk disease: del(17p) or del(11q)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/1\">",
"      Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010; 21:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/2\">",
"      Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013; 31:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/3\">",
"      Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012; 11:CD008079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/4\">",
"      Wierda WG, Kipps TJ, D&uuml;rig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117:6450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/5\">",
"      Cazin B, Divine M, Lepr&ecirc;tre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008; 143:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/6\">",
"      Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/7\">",
"      Steurer M, Pall G, Richards S, et al. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2006; :CD004270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/8\">",
"      Rai KR, Peterson BL, Appelbaum FR, et al. Long-term survival analysis of the north american intergroup study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (abstract 536). Blood 2009; 114:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/9\">",
"      Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/10\">",
"      Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/11\">",
"      Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/12\">",
"      Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/13\">",
"      Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012; 119:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/14\">",
"      Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer 2012; 118:3954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/15\">",
"      Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/16\">",
"      Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/17\">",
"      Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/18\">",
"      Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011; 29:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/19\">",
"      Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/20\">",
"      Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/21\">",
"      Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012; 159:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/22\">",
"      Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/23\">",
"      Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/24\">",
"      Samaniego F, Fanale M, Pro B, et al. Pentostatin, cyclophosphamide, and rituximab achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression (abstract 835). Blood 2008; 112:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/25\">",
"      Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/26\">",
"      Oken MM, Lee S, Kay NE, et al. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 2004; 45:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/27\">",
"      Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/28\">",
"      Kay NE, Wu W, Kabat B, et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010; 116:2180.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.campath.com/index.html (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/30\">",
"      Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/31\">",
"      O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/32\">",
"      Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/33\">",
"      Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/34\">",
"      Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/35\">",
"      Lundin J, Kimby E, Bj&ouml;rkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/36\">",
"      Lepretre S, Aurran T, Mah&eacute; B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119:5104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/37\">",
"      Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011; 118:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/38\">",
"      Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/39\">",
"      Gribben JG. How I treat CLL up front. Blood 2010; 115:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/40\">",
"      Polizzotto MN, Tam CS, Milner A, et al. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 2006; 107:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/41\">",
"      Danese MD, Griffiths RI, Gleeson M, et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood 2011; 117:3505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/42\">",
"      D&ouml;hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/43\">",
"      Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/44\">",
"      Ravandi F, O'brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/45\">",
"      Osuji NC, Del Giudice I, Matutes E, et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/46\">",
"      Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/47\">",
"      Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009; 144:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/48\">",
"      Hainsworth JD, Vazquez ER, Spigel DR, et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 112:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/49\">",
"      Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010; 28:4500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/13/6362/abstract/50\">",
"      Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012; 30:1647.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83749 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6362=[""].join("\n");
var outline_f6_13_6362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5623578\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5623314\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5622415\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1664568\">",
"      Our general approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5622422\">",
"      Fludarabine-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23868573\">",
"      - Choice of fludarabine regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5622436\">",
"      - Fludarabine, cyclophosphamide, and rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23868398\">",
"      - Fludarabine plus rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23868301\">",
"      Bendamustine-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23868177\">",
"      Pentostatin-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23869242\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5624009\">",
"      SPECIAL PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5624031\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5624038\">",
"      High-risk disease: del(17p) or del(11q)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5623578\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/83749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/3/22590\" title=\"table 1\">",
"      FCR for CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1550\" title=\"table 2\">",
"      FR for CLL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_13_6363="Indoor fungi";
var content_f6_13_6363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common indoor fungi",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <em>",
"         Cladosporium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Alternaria",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Epicoccum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Fusarium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Penicillium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Aspergillus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Geotrichum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Rhodotorula",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Chaetomium",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Bush, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6363=[""].join("\n");
var outline_f6_13_6363=null;
var title_f6_13_6364="High risk conditions for invasive pneumococcal disease";
var content_f6_13_6364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Underlying medical conditions that are indications for pneumococcal polysaccharide vaccination among children, by risk group - Advisory Committee on Immunization Practices (ACIP), United States, 2010",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Immunocompetent children",
"       </td>",
"       <td>",
"        Chronic heart disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lung disease",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrospinal fluid leaks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cochlear implant",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Children with functional or anatomic asplenia",
"       </td>",
"       <td>",
"        Sickle cell disease and other hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital or acquired asplenia, or splenic dysfunction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Children with immunocompromising conditions",
"       </td>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure and nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; or solid organ transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital immunodeficiency",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Particularly cyanotic congenital heart disease and cardiac failure.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Including asthma if treated with prolonged high-dose oral corticosteroids.",
"      <br>",
"       &Delta; Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From Centers for Disease Control and Prevention. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59:260.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6364=[""].join("\n");
var outline_f6_13_6364=null;
var title_f6_13_6365="Path mastect occ prim breast CA";
var content_f6_13_6365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathologic findings at mastectomy in patients with occult primary breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mastectomy, n",
"       </td>",
"       <td class=\"subtitle1\">",
"        In situ, n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Invasive, n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cancer, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Owens, H; 1954",
"       </td>",
"       <td>",
"        1907-50",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feuerman, L; 1962",
"       </td>",
"       <td>",
"        1949-61",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fitts, W; 1963",
"       </td>",
"       <td>",
"        1948-63",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haagensen, C; 1974",
"       </td>",
"       <td>",
"        1916-66",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ashikari, R; 1976",
"       </td>",
"       <td>",
"        1946-75",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patel, J; 1981",
"       </td>",
"       <td>",
"        1952-79",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kemeny, M; 1986",
"       </td>",
"       <td>",
"        1973-85",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bhatia, S; 1987",
"       </td>",
"       <td>",
"        1977-85",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baron, P; 1990",
"       </td>",
"       <td>",
"        1975-78",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ellerbroek, N; 1990",
"       </td>",
"       <td>",
"        1944-87",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Merson, M; 1992",
"       </td>",
"       <td>",
"        1945-87",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feigenberg, S; 2003",
"       </td>",
"       <td>",
"        1971-74",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blanchard, D; 2004",
"       </td>",
"       <td>",
"        1975-98",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        234",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6365=[""].join("\n");
var outline_f6_13_6365=null;
var title_f6_13_6366="Contents: Non pain symptoms: Assessment and management";
var content_f6_13_6366=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?34/55/35709\">",
"       Palliative Care",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Non pain symptoms: Assessment and management",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Non pain symptoms: Assessment and management",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19273\">",
"           Cardiac tamponade",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19338\">",
"           Malignancy-related superior vena cava syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1050\">",
"           Pericardial disease associated with malignancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/3/7226\">",
"           Malignancy-associated gastroparesis: Pathophysiology and management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41178\">",
"           Approach to symptom assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8072\">",
"           Withdrawal from and withholding of dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropsychiatry",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6922\">",
"           Palliative care: Overview of fatigue, weakness, and asthenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition/fluids/metabolic",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34215\">",
"           Failure to thrive in elderly adults: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42455\">",
"           Failure to thrive in elderly adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39928\">",
"           Malignancy-related ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/39/43639\">",
"           Nutritional support in advanced lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/63/20473\">",
"           Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/60/30666\">",
"           Assessment and management of dyspnea in palliative care",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B2280EB4B5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_13_6366=[""].join("\n");
var outline_f6_13_6366=null;
var title_f6_13_6367="Platelet production per nucleus";
var content_f6_13_6367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Megakaryocyte volume and platelet production per nucleus in megakaryocyte disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow analysis was performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The amount of megakaryocyte cytoplasm per diploid (2N) amount of nuclear DNA was similar to normal in all of the disorders. Right panel: When the platelet production rate was measured in kinetic studies and then divided by the number of diploid nuclear lobes of the megakaryocyte, the amount of platelets produced per diploid amount of nuclear DNA was normal in all disorders except for hypoplastic marrow states and B12 deficiency in which ineffective thrombopoiesis was present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_13_6367=[""].join("\n");
var outline_f6_13_6367=null;
             